Skip to content

US · TVRD · BIOTECHNOLOGY

Tvardi Therapeutics, Inc. (TVRD) intrinsic value and stock valuation

$0.99as of 2026-11-21 · Mkt cap 18.76M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tvardi Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TVRD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TVRD’s statements →

Tvardi Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Sugar Land, TX 77478 tvarditherapeutics.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-18.21M
20202025
Free cash flow
-$-23.5M
20202025
Total equity
$21M-39% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$7.14M$21M$41.9M$23M
Operating income-$-26.75M-$-55.78M-$-121.5M-$-87.53M-$-89.08M
Net income-$-18.21M-$-70.87M-$-118.51M-$-85.47M-$-88.44M
EPSd-$-2.34M-$-46.63M-$-12.66M-$-9.13M-$-62.72M
Operating cash flow-$-23.5M-$-60.92M-$-21.04M-$-17.87M-$-60.09M
Capital expenditure$0.00-$-1.05M-$-2.38M-$-50K-$-40K
Free cash flow-$-23.5M-$-61.96M-$-21.04M-$-17.92M-$-60.13M
Total assets$32.1M$43.8M$27M$45.1M$247.1M
Total debt$200K$44.5M$370K$2.37M$3.67M
Net debt-$-20.53M$6.54M-$-22.55M-$-19.12M-$-9.78M
Total equity$21M-$-4.59M-$-62.06M-$-45.05M$227.5M
Cash and short-term investments$30.8M$37.9M$22.9M$43.7M$167M
Income statement
20252024202320222021
Revenue$0.00$7.14M$21M$41.9M$23M
Cost of revenue$100K$810K$6.43M$7.51M$1.55M
Gross profit-$-100K$6.33M$14.5M$34.4M$21.5M
Research and development expenses$18M$32.8M$108.4M$91.8M$82.6M
Selling, general and administrative expenses$8.74M$26.4M$27.7M$30.1M$28M
Other expenses$0.00$2.96M$0.00$0.00$0.00
Operating expenses$26.8M$62.1M$136M$121.9M$110.6M
Cost and expenses$26.8M$62.9M$142.5M$129.4M$112.1M
Interest income$1.38M$2.83M$1.32M$650K$600K
Interest expense$0.00$8.47M$0.00$0.00$0.00
Depreciation and amortization$100K$190K$260K$1.67M$1.55M
Ebitda-$-18.12M-$-62.6M-$-117.65M-$-83.8M-$-86.89M
Operating income-$-26.75M-$-55.78M-$-121.5M-$-87.53M-$-89.08M
Total other income/expenses, net$8.53M-$-15.48M$2.98M$2.06M$640K
Income before tax-$-18.21M-$-71.27M-$-118.51M-$-85.47M-$-88.44M
Income tax expense$0.00-$-400K$0.00$0.00$0.00
Net income-$-18.21M-$-70.87M-$-118.51M-$-85.47M-$-88.44M
Weighted average shares outstanding$7.42M$1.52M$9.36M$9.36M$1.41M
Weighted average diluted shares outstanding$7.78M$1.52M$9.36M$9.36M$1.41M
Balance sheet
20252024202320222021
Cash and short-term investments$30.8M$37.9M$22.9M$43.7M$167M
Net receivables$0.00$4.5M$4.02M$4.45M$1.15M
Inventory$0.00$900K$0.00$0.00$2.58M
Total current assets$31.5M$43.8M$26.2M$44.1M$173.3M
Property, plant and equipment, net$200K$0.00$380K$460K$3.6M
Goodwill and intangible assets$320K$0.00$450K$510K$0.00
Long-term investments$0.00$0.00$1.5M$11.4M$70.2M
Total non-current assets$540K$0.00$840K$990K$73.8M
Total assets$32.1M$43.8M$27M$45.1M$247.1M
Accounts payable$3.22M$1.43M$1.61M$2.41M$5.62M
Short-term debt$120K$0.00$90K$2M$1.75M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11M$3.97M$3.28M$4.28M$17.6M
Long-term debt$90K$44.5M$280K$370K$1.92M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$90K$44.5M$85.8M$85.9M$1.92M
Capital lease obligations$200K$0.00$370K$450K$1.92M
Total liabilities$11.1M$48.4M$89.1M$90.2M$19.5M
Common stock$10K$10K$20K$20K$50K
Retained earnings-$-110.45M-$-755.61M-$-62.84M-$-45.49M-$-480.76M
Accumulated other comprehensive income (loss)$10K$0.00$0.00-$-20K-$-360K
Total equity$21M-$-4.59M-$-62.06M-$-45.05M$227.5M
Total investments$10.1M$0.00$1.5M$33.6M$223.7M
Total debt$200K$44.5M$370K$2.37M$3.67M
Net debt-$-20.53M$6.54M-$-22.55M-$-19.12M-$-9.78M
Cash flow statement
20252024202320222021
Net income-$-18.21M-$-70.87M-$-17.35M-$-20.54M-$-88.44M
Depreciation and amortization$100K$190K$100K$90K$1.55M
Stock-based compensation$1.4M$0.00$310K$250K$0.00
Change in working capital$510K-$-15.1M-$-3.96M$2.67M$5.26M
Accounts receivable$0.00$2.02M$0.00-$-3.3M$910K
Inventory$0.00-$-1.04M$0.00$0.00-$-2.58M
Accounts payable$0.00-$-21.44M$0.00$5.68M-$-1.02M
Net cash provided by operating activities-$-23.5M-$-60.92M-$-21.04M-$-17.87M-$-60.09M
Investments in property, plant and equipment$0.00-$-1.05M-$-2.38M-$-50K-$-40K
Acquisitions, net$0.00$0.00$0.00$0.00$70K
Net cash used for investing activities-$-10.08M$48.7M$22.5M-$-22M-$-4.75M
Common stock issued$530K$0.00$0.00$0.00$46.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$22.7M-$-3.6M$0.00$0.00$46.6M
Net change in cash-$-10.88M-$-14.28M$1.43M-$-39.86M-$-18.23M
Cash at end of period$20.7M$37.9M$22.9M$21.5M$13.5M
Operating cash flow-$-23.5M-$-60.92M-$-21.04M-$-17.87M-$-60.09M
Capital expenditure$0.00-$-1.05M-$-2.38M-$-50K-$-40K
Free cash flow-$-23.5M-$-61.96M-$-21.04M-$-17.92M-$-60.13M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tvardi Therapeutics, Inc.

        Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

        CEO
        Imran Alibhai
        Employees
        12
        Beta
        0.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Tvardi Therapeutics, Inc. (TVRD)?

        InvestorsCraft does not currently publish an intrinsic value for TVRD. How the IC value is calculated.

        Is TVRD undervalued?

        InvestorsCraft does not publish an undervaluation signal for TVRD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.